China Universal Asset Management Co., Ltd. Inozyme Pharma, Inc. Transaction History
China Universal Asset Management Co., Ltd.
- $1.05 Billion
- Q1 2025
A detailed history of China Universal Asset Management Co., Ltd. transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 12,885 shares of INZY stock, worth $51,282. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,885
Previous 13,621
5.4%
Holding current value
$51,282
Previous $37,000
70.27%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding INZY
# of Institutions
97Shares Held
46MCall Options Held
13.8KPut Options Held
1K-
Adage Capital Partners Gp, L.L.C. Boston, MA5.16MShares$20.5 Million0.01% of portfolio
-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA4.49MShares$17.9 Million5.72% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA4.28MShares$17 Million0.29% of portfolio
-
Affinity Asset Advisors, LLC New York, NY3.87MShares$15.4 Million0.39% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD3.45MShares$13.7 Million0.19% of portfolio
About Inozyme Pharma, Inc.
- Ticker INZY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,145,700
- Market Cap $160M
- Description
- Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...